You are viewing your 1 free article this month. Login to read more articles.
Pharmaceuticals giant Pfizer has partnered up with publisher BioMed Central to launch an open access waiver fund to support medical scientists in developing countries, according to UPI.com.
The deal will allow automatic waivers of publication fees for authors from low-income countries, allowing them to publish their research articles in BioMed Central's open access journals without paying a publication fee.
Jack Watters, vice-president for Pfizer's external medical affairs, was reported as saying the firm's support for open access publishing was "driven by a recognition of the wide benefits of global access to the latest research results, and the crucial role that open access journals can play in the communication of those results".
He added: "We feel that it is critically important that the benefits of scientific publication are extended to all scientists who do quality research, and that providing this access will promote much-needed recognition of research conducted in developing countries."